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ABSTRACT 
Natural killer cells (NK-cells) are believed to play an essential role in the immune 
surveillance against tumors and infectious diseases.  The role of NK-cells in colon cancer 
remains obscure, since increased as well as decreased percentages and/or activity of NK-cells 
in comparison to control patients have been reported. Percentage and cytolytic activity of NK-
cells in the peripheral blood were analyzed in 42 patients with colon cancer before surgery 
and one year thereafter in comparison to control patients with non-malignant diseases. 
Patients without distant metastasis at the time of diagnosis displayed a significantly increased 
percentage of NK-cells as well as sustained NK-cell activity in the peripheral blood prior to 
surgery when compared to control patients. In contrast, patients with metastatic disease at the 
time of diagnosis displayed significantly decreased NK-cell activity in the peripheral blood 
when compared to control patients. One year after surgery, patients who remained free of 
metastasis still displayed sustained NK-cell activity, whereas patients who developed 
metastasis presented with profoundly decreased levels of NK-cell activity. Further analysis of 
these patients revealed that patients who developed metastasis within the first year after 
surgery already displayed reduced NK-cell activity prior to curative colorectal surgery. These 
observations indicate that metastatic spread of colorectal cancer is associated with decreased 
NK-cell activity. It remains speculative whether decreased NK-cell activity precedes the 
development of metastasis and thus may help to identify patients with a high risk of rapid 
tumor progression following curative colorectal surgery. 
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INTRODUCTION 
 
Natural killer (NK) cells are CD3- 
lymphocytes, expressing CD16 and/or CD56 
and account for up to 15% of human 
peripheral blood lymphocytes. In addition to 
their distinct phenotype, NK-cells can be 
distinguished from naive T and B 
lymphocytes by their capability to kill a 
variety of target cells including solid tumor 
cells, leukemia cells and virus-infected target 
cells as well as cells without MHC 
expression (Brittenden et al., 1996; Sandel et 
al., 2005). Due to the broad range of 
potential target cells and the capability of 
lysing target cells “spontaneously” without 
prior sensitization, NK-cells are believed to 
play an essential role in the immune 
surveillance against tumors and infectious 
diseases (Brittenden et al., 1996; Hanna et 
al., 1982). 
 
In malignancy, NK-cells appear to represent 
a first line of defense against the metastatic 
spread of tumor cells (Gorelik et al., 1982). 
Evidence for this hypothesis came from 
animal studies revealing rapid metastatic 
spread of cancer in the absence of NK-cells 
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(Gorelik et al., 1982). In accordance with 
these observations decreased activity or low 
numbers of circulating NK-cells in 
comparison to control patients have been 
reported to be associated with progression of 
cancer in humans (Chuang et al., 1990; 
Gonzalez et al., 1998; Lahat et al., 1989; 
Kondo et al., 2003).  However, there are also 
reports about unchanged numbers and 
sustained activity of NK-cells in patients 
with malignant disease (Aparicio-Pages et 
al., 1989; Bonilla et al., 1990). 
 
Conflicting results have also been obtained in 
patients with colon cancer. Decreased NK-
cell activity in comparison to control patients 
has been observed irrespective of disease 
activity or in patients with advanced disease 
only. Other studies reported unchanged or 
even increased NK-cell activity in patients 
with colorectal cancer (Kondo et al., 2003; 
Aparicio-Pages et al., 1989; Koda et al., 
2003; Tartter et al., 1987; Liljefors et al., 
2003). Due to these discrepancies, the 
prognostic significance of NK-cell numbers 
and NK-cell activity in patients with colon 
cancer remains to be fully elucidated. 
 
In the present study NK-cell number and 
activity in the peripheral blood were 
analyzed in 42 patients with colon cancer 
with or without distant metastasis in 
comparison to control patients with non-
malignant diseases. In order to evaluate 
alterations of the percentage and activity of 
NK-cells during the course of the disease, all 
patients with colon cancer were examined 
prior to surgery and one year thereafter with 
particular emphasis on metastatic spread of 
the tumor. 
 
Patients with primary non-metastatic cancer, 
who remained free of metastasis during the 
observation period displayed levels of NK-
cell activity comparable to control patients 
prior to surgery and one year thereafter.  In 
contrast, patients who developed metastasis 
after curative surgery displayed decreased 
NK-cell activity one year after surgery, 
thereby resembling patients who presented 
with metastasis at the time of diagnosis. 
Retrospective analysis of the five patients 
who developed metastasis within one year 
after surgery revealed that these patients 
already presented with low levels of NK-cell 
activity prior to surgery. These observations 
indicate that metastatic spread of colorectal 
cancer surgery may be associated with 
decreased NK-cell activity in the peripheral 
blood. A possible prognostic significance of 
decreased NK-cell activity remains to be 
elucidated. 
 
 
MATERIAL AND METHODS 
 
Patients studied 
50 patients with colon cancer were included 
in this study. 6 patients refused the follow-up 
analysis one year after surgery, 2 patients 
were lost in follow-up. These 8 patients were 
excluded from the analysis. The remaining 
42 patients with colon cancer were 
retrospectively divided into three groups 
according to disease stage and tumor 
progression during follow-up: 
 
A: patients with initially non-metastatic 
colon cancer who remained free of 
metastatic tumor growth within the first 
year after primary surgery (“without 
metastasis”, n= 15). This group consisted 
of 8 men and 7 women with a mean age of 
65±17 years (range 48-81 years). 
 
B: patients with initially non-metastatic 
colon cancer who developed metastatic 
tumor growth within the first year after 
primary surgery (“metachronous 
metastasis”, n=5). This group consisted of 
2 men and 3 women with a mean age of 
55±18 years (range 41-79 years). 
 
C: patients with metastatic tumor growth at 
the time of diagnosis (“synchronous 
metastasis”, n=22). This group consisted 
of 12 men and 10 women with a mean age 
of 63±24 years (range 41-88 years). 
 
Patients undergoing surgery for non-
malignant disease (cholecystolithiasis, 
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inguinal hernia or peripheral vascular 
disease) served as control group (n=20).  
This group consisted of 9 men and 11 women 
with a mean age of 59±28 years (range 45-88 
years). Patients with benign inflammatory 
diseases (cholecystitis, colitis, diverticulitis) 
were excluded from the control group, in 
order to avoid effects of the inflammatory 
processes on NK-cell function. 
 
Patients with initially non-metastatic tumor 
(group A and B) underwent elective 
colorectal cancer surgery. In all cases 
diagnosis and stage of disease were 
confirmed by histopathological examination 
of the resected specimens. TNM and UICC 
stages are depicted in Table 1. 
 
Table 1: Tumor stages of 42 patients with colon cancer. 
 
 Group A 
without metastasis, n=15 
n (%) 
Group B 
metachronous metastasis, n=5 
n (%) 
Group C 
synchronous metastasis, n=22
n (%) 
T1  - - - 
T2 5 (33.3) 1 (20.0) 5 (22.7) 
T3 9 (60.0) 2 (40.0) 13 (59.1) 
T4 1 (6.7) 2 (40.0) 4 (18.2) 
UICC I 4 (26.7) 1 (20.0) - 
UICC II 6 (40.0) 1 (20.0) - 
UICC III 5 (33.3) 3 (80.0) - 
UICC IV - - 22 (100.0) 
 
Patients with advanced metastatic colon 
cancer (group C) were admitted to the 
hospital either for surgery or chemotherapy. 
16 of the 22 patients had liver metastases, 
three patients presented with pulmonary 
metastasis and three patients showed 
ubiquitous tumor growth.  
The study was approved by the ethics 
committee of the Humboldt University and 
all patients gave written informed consent 
prior to enrollment in the study. 
 
Venous blood samples were obtained from 
all patients one day prior to surgery or prior 
to chemotherapy. Patients of Group A and B 
were re-examined one year after primary 
surgery. At that time point patients 
underwent abdominal ultrasound, chest x-
ray, analysis of tumor marker levels (CEA 
and CA19-9) in the peripheral blood as well 
as CT scan when indicated in order to screen 
for distant metastasis. 
 
Isolation of PBL 
Peripheral blood lymphocytes were isolated 
from heparinized venous blood samples by 
Ficoll hypaque density gradient 
centrifugation. All blood samples were 
obtained before surgery or before 
chemotherapy. Isolated lymphocytes were 
cultured at 37°C and 5% CO2 (v/v) in RPMI 
1640 medium (Gibco BRL, USA) 
supplemented with 1mM sodium pyruvate, 
0.1 mM non-essential amino acids, 2mM L-
glutamine, 100U/ml penicillin, 0.1 mg/ml 
streptomycin, 0.05 mM 2-mercaptoethanol 
and 5% heat-inactivated fetal calf serum 
(FCS) (Gibco BRL, USA). 
 
Phenotype analysis of PBL 
Phenotype analysis of peripheral blood 
lymphocytes was performed by two-color 
flow cytometry . The following monoclonal 
antibodies were used: FITC mouse anti-
human CD3 (clone UCHT1), PE and FITC 
mouse anti-human CD16 (3G8) and PE 
mouse anti-human CD56 (B159) all 
purchased from Pharmingen (San Diego, CA, 
USA). 
 
For staining, 100 μl heparinized blood was 
incubated with FITC and PE-labeled 
antibodies for 30 min. at 4°C. Red blood 
cells were lysed by addition of FACS Lysing 
Solution (Becton Dickinson& Co., Mountain 
View, CA, USA) for 10 minutes at room 
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temperature. Cells were washed three times 
in FACS medium and fixed in 1% 
paraformaldehyde solution. Two-color 
cytofluorometric analysis was performed on 
a FACScan (Becton Dickinson, Mountain 
View, CA ). A total of 20.000 events were 
counted, after dead cells and epithelial cells 
had been excluded by gating on forward and 
side light scatter. Percentages reported are 
based on cells in the gated region only. Data 
were analyzed using Cell Quest software 
(Becton Dickinson & Co., Mountain View, 
CA). 
 
Cytotoxicity assay 
Cytotoxicity was measured in a [51-Cr] 
release assay against the human colonic 
adenocarcinoma cell line DLD-1 and the 
NK-sensitive cell line K-562. Target cells 
were labeled with 51NaCr2O3 (200µCi/5x106 
cells) (ICN, Eschwege, Germany) for one 
hour at 37°C and were washed three times in 
RPMI 1640. Target cells were then plated in 
triplicates at 2x103 cells/well in 96-well 
microtiter plates. Effector cells were plated 
into the wells in various numbers in order to 
give effector:target ratios ranging from 10:1 
to 200:1 in a total volume of 200µl. After a 
16-h-incubation period at 37°C, cells were 
pelleted by centrifugation. Supernatants were 
collected for determination of radioactivity 
using a γ-counter (1470 Wizard, Wallac, 
Albertville, USA). Cytotoxicity was 
calculated as : % target cell lysis = (sample 
release - spontaneous release) / (maximal 
release - spontaneous release) × 100. 
Spontaneous release was < 10%. 
 
Statistics 
For each set of data, the mean and standard 
error of the mean were calculated. Student´s 
t-test was performed to determine differences 
between the study groups.  
Significance was reached at p<0.05. 
 
 
 
 
 
 
RESULTS 
 
Increased percentage of NK-cells in the 
peripheral blood of patients with primary 
non-metastatic colon cancer. 
The first experiments were conducted in 
order to analyze the percentage of NK-cells 
in the peripheral blood of patients with 
primary non-metastatic colorectal cancer in 
comparison to patients with metastatic 
disease and control patients (Table 2).  In 
control patients CD3-CD16+ NK-cells 
accounted for 11.9% of isolated PBL. All 
patients without metastasis at the time of 
diagnosis (group A and B) displayed a 
significantly increased percentage of NK-
cells in the peripheral blood when compared 
to control patients (Table 2). This increased 
percentage of NK-cells could be detected 
prior to surgery in patients who remained 
free of metastasis after surgery (group A) as 
well as in patients who experienced 
metastatic tumor spread within the first 
postoperative year (group B). The latter 
presented with the highest percentage of NK-
cells (21.4%) of all groups before surgery. 
Patients without metastasis before surgery 
also showed a slight increase of CD3-CD56+ 
NK-cells in the peripheral blood when 
compared to control patients, but this 
difference did not reach statistic significance. 
In contrast, patients with already established 
metastasis (group C) did not display changes 
in the number of CD3-CD16+ or CD3-CD56+ 
NK-cells when compared to control patients 
(Table 2). 
One year after surgery, patients who 
remained free of metastatic tumor growth 
(group A) still displayed an increased 
percentage of NK-cells in the peripheral 
blood (Table 2). In contrast, patients who had 
developed metastasis (group B) presented 
with a percentage of NK-cells 
undistinguishable from control patients, but 
profoundly decreased in comparison to their 
preoperative values. This observations show, 
that metastatic spread of colorectal cancer is 
not associated with significant alterations of 
the percentage of NK-cells in the peripheral 
blood when compared to control patients. 
However, a decrease of preoperatively 
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increased percentages of NK-cells may 
indicate metastatic spread in patients with 
initially non-metastatic colorectal cancer. 
 
Table 2: Percentage of NK-cells in the peripheral blood of patients with colon cancera 
 
 Control 
 
n=20 
Group A 
without metastasis 
n=15 
Group B 
metachronous metastasis 
n=5  
Group C 
synchronous metastasis
n=22 
preop     
CD3-CD16+ 11.9 ± 6.5 16.4 ± 5.1* 21.4 ± 5.6* 13.6 ± 6.7 
CD3-CD56+ 12.2 ± 7.0 12.8± 7.5 15.2 ± 5.8 11.7 ± 4.8 
postop     
CD3-CD16+  17.9 ± 7.3* 13.0 ± 1.8  
CD3-CD56+  18.3 ± 6.5* 11.5 ± 2.0  
 
aPhenotypic analysis of peripheral blood lymphocytes was performed in patients with colon 
cancer with and without metastasis and control patients prior to surgery and one year 
thereafter. Utilizing two-color FACS analysis, the percentages of the various lymphocyte 
subsets were determined. Values are depicted as mean ± SEM of all patients in each group. 
*p<0.05 vs. control patients. 
 
Cytolytic NK-cell activity is reduced in 
patients with metastatic colon cancer. 
A characteristic function of NK-cells is their 
spontaneous cytotoxicity which can be 
analyzed in a 51[Cr]-release assay against the 
human NK-sensitive K-562 cells (Table 3, 
Figure 1).  
 
Table 3: NK-cell activity of isolated PBL in relation to tumor stagea 
 
 
 
tumor stage 
Control 
 
n=20 
Group A 
without metastasis 
n=15 
Group B 
metachronous metastasis 
n=5  
Group C 
synchronous metastasis
n=22 
preop     
mean 41.1±5.8 50.0±7.4 11.1±2.5* 21.1±3.6* 
UICC I  45.6±6.8 12.5#  
UICC II  56.2±7.9 7.9#  
UICC III  39.4±7.3 11.8±2.7*  
UICC IV    21.1±3.6* 
postop     
mean 41.1±5.8 41.6±6.9 14.2±4.8* 21.1±3.6* 
 
a PBL were isolated from heparinized venous blood samples and cytolytic activity of the isolated 
cells was tested against the NK-sensitive cell line K-562 in a [51-Cr] release assay. Results are 
depicted as % target cell lysis at an effector:target ratio of 200:1 (mean±SEM of all patients in 
each group). # group consisted of only one patient. * p<0.05 versus control 
 
Specific cytotoxicity of PBL was tested 
against the human adenocarcinoma cells 
DLD-1.  Cytolytic activity was tested prior to 
surgery and one year thereafter. 
 
PBL from control patients displayed 
cytolytic activity against K-562 cells (Figure 
1a) and to a lesser degree against the human 
colon carcinoma cells DLD-1 (Figure 1b).   
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Figure 1: Preoperative cytotoxicity of isolated PBL from patients with colon cancer and control 
patients.  
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PBL were isolated from heparinized venous blood samples of control patients (open diamonds), 
patients without metastasis (A, closed triangles), patients with metachronous metastasis (B, 
closed squares) or patients with synchronous metastasis (C, closed circles) prior to surgery.  
Cytolytic activity of the isolated cells was tested against the NK-sensitive cell line K-562 (upper 
panel, a) and the colon carcinoma cell line DLD-1 (lower panel, b) in a [51-Cr] release assay. 
Results are depicted as % target cell lysis at various effector : target ratios (mean ± SEM of all 
patients in each time group). 
* p<0.05  versus control patients. 
 
In comparison, PBL from patients with 
established metastatic tumor growth (Group 
C) displayed significantly decreased 
cytolytic activity against both, the NK-
sensitive target K-562, and the colon cancer 
cells DLD-1 (Figure 1a and 1b). This 
reduced NK-activity in these patients was not 
due to a reduced number of peripheral NK-
cells, since the percentage of NK-cells in 
patients with metastatic tumor growth was 
similar to the percentage of NK-cells in 
control patients at that time point (Table 2). 
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Patients with initially non-metastatic colon 
cancer who remained free of metastasis 
during the observation period (Group A) 
were capable of mounting a cytolytic 
response against K-562 cells preoperatively 
comparable to control patients (Figure 1a). 
The cytolytic activity against DLD-1 cells 
was significantly increased in these patients 
(Figure 1b). It has to be noted, that patients 
with non-metastatic tumor growth displayed 
an increased percentage of NK-cells at that 
time point (Table 2) suggesting an impaired 
function of the cytolytic cells. Similar results 
were obtained one year after surgery. At that 
time point, the level of NK-cell activity of 
patients without distant metastasis was again 
comparable to the level of NK-cell activity of 
control patients (Table 3). 
 
Different results were obtained from the five 
patients who experienced metastatic spread 
after curative surgery (Group B) (Table 3 and 
Figure 1). They showed a significant 
reduction of the cytolytic activity of 
peripheral blood lymphocytes against both 
targets before surgery, i.e. before the 
development of metastasis when compared to 
control patients (Figure 1).  This decreased 
NK-activity was observed despite the 
significantly increased percentage of NK-
cells in the peripheral blood (Table 2) 
pointing towards a profound disturbance of 
NK-cell function. One year after surgery, 
when metastasis had been detected in these 
five patients, their level of NK-cell activity 
was again undistinguishable from the NK-
cell activity of patients who had presented 
with metastasis at the time of diagnosis 
(group C) (Table 3).  
 
These observations suggest that reduced NK-
cell activity is associated with metastatic 
tumor growth in patients with colon 
carcinoma. A possible prognostic 
significance of preoperatively reduced NK-
cell activity in patients with colorectal cancer 
could be hypothesized. 
 
 
 
 
DISCUSSION 
 
Soon after the discovery of NK-cells in 1975 
and the description of their spontaneous, so 
called “natural” cytotoxicity, it was realized 
that these cells may play an important role in 
the host defense against tumors (Eremin et 
al., 1978). Various studies have been carried 
out since then, trying to establish a 
connection between tumor spread and 
percentage or activity of NK-cells. Until now 
contradictory observations have been made. 
Many investigators have found either 
decreased percentages of circulating NK-
cells or decreased activity of isolated NK-
cells in patients with advanced malignancies 
when compared to control patients 
(Brittenden et al., 1996; Chuang et al., 1990; 
Lahat et al., 1989; Tartter et al., 1987). In 
contrast, other studies revealed no changes in 
the cytolytic activity of NK-cells in patients 
with cancer (Aparicio-Pages et al., 1989; 
Bonilla et al., 1990; Gati et al., 2001) or even 
observed an increased activity of NK-cells in 
tumor patients in comparison to control 
patients (Liljefors et al., 2003; Nio et al., 
1991). 
 
In this study, decreased NK-cell activity in 
comparison to control patients was observed 
in patients with metastatic colon cancer and 
in patients with primary non-metastatic colon 
cancer who developed distant metastasis 
within one year after surgery. Both, patients 
with established metastasis as well as 
patients who developed metastasis following 
curative surgery for initially non-metastatic 
disease presented severely impaired NK-cell 
activity when compared to patients who 
remained free of metastatic spread or control 
patients. Similar observations have been 
made by Kondo et al. who reported about an 
increased risk of metachronous colorectal 
metastasis in patients with decreased NK-cell 
activity (Kondo et al., 2003). The importance 
of NK-cells in the host defense against 
malignant tumors had also been pointed out 
in other studies which showed that sustained 
NK-activity was associated with better 
survival in patients with laryngeal or colon 
cancer and decreased NK-activity predicted 
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poor prognosis in patients with metastatic 
colon cancer (Gonzalez et al., 1998; Liljefors 
et al., 2003). 
 
Interestingly, the preoperative level of 
cytolytic activity of NK-cells in patients with 
colon cancer in this study did not correlate 
with the tumor stage. Among patients who 
remained free of metastasis, the level of NK-
cell activity was not different between UICC 
I, II or III patients. Similarly all five patients 
who later developed metastasis displayed 
decreased levels of NK-cell activity prior to 
surgery, irrespective of their UICC stage. 
And although the significance of this 
observation is somewhat limited due to the 
small number of patients in this group, it 
could be hypothesized that a preoperatively 
reduced level of NK-cell activity compared 
to control patients may point towards an 
increased risk of metastatic tumor growth 
following curative colorectal surgery. 
Certainly, this hypothesis needs to be 
validated in larger studies. 
 
The observation that both, patients with 
metachronous or synchronous metastasis 
displayed decreased NK-activity despite 
normal or even increased percentages of 
circulating NK-cells when compared to 
control patients further supports the 
hypothesis of profound disturbances of NK-
cell function in these patients. However, 
impaired NK-cell function must also be 
assumed in patients who remained free of 
metastasis after colorectal surgery. In these 
patients the sustained level of NK-cell 
activity was achieved by increased 
percentages of NK-cells in the peripheral 
blood, suggesting a reduction of NK-cell 
activity compensated by the higher number 
of circulating NK-cells. Similar observations 
have been made by Berghella et al. 
(Berghella et al., 1994), who have shown an 
increased percentage of circulating NK-cells, 
but decreased activity of the isolated NK-
cells in patients with advanced cancer. 
Suppressive factors, such as soluble MHC 
class I chain related molecules (MIC) which 
are downmodulating receptors on NK-cells 
have been hypothesized to be responsible for 
this impairment of NK-cell function in 
malignant disease (Brittenden et al., 1996; 
Doubrovina et al., 2003). Furthermore, stress 
and surgical interventions as well as 
chemotherapy may account for disturbances 
of NK-cells in cancer (Koda et al., 2003; 
Ben-Eliayahu et al., 1990). 
 
In summary, NK-cell activity seems to be an 
important host defense mechanism against 
metastatic spread of colon cancer. Our data 
suggest that decreased NK-cell activity may 
be associated with metastatic disease. The 
prognostic significance of decreased NK-cell 
activity in patients with initially non-
metastatic colon cancer needs to be 
elucidated.  
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